UK Markets closed

Orion Corporation: Transfer of 99,768 own B shares on 1 March 2021

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
Orion Oyj
·2-min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

ORION CORPORATION STOCK EXCHANGE RELEASE 1 MARCH 2021 at 18.45 EET

Orion Corporation: Transfer of 99,768 own B shares on 1 March 2021

In accordance with a decision by the Board of Directors, Orion Corporation has on 1 March 2021 transferred altogether 99,768 Orion Corporation B shares held by the company as a share reward for earning periods 2018–2020 and 2019–2020 to the persons belonging to the Share-based Incentive Plan of the Orion Group. The transfer is based on the authorisation by the Annual General Meeting of 26 March 2019.

The price per share of the transferred shares is EUR 34.1055, which is the volume weighted average quotation of the Orion Corporation B share on 1 March 2021. Accordingly, the total transaction price of the transferred shares is EUR 3,402,637.52.

After the share transfer, the total number of own B shares held by Orion Corporation is 571,314.

Orion Corporation has informed about the Share-based Incentive Plans in stock exchange releases on 2 February 2016 and on 6 February 2019.

Orion Corporation

Timo Lappalainen
President and CEO

Olli Huotari
SVP, Corporate Functions



Contact person:
Olli Huotari, SVP, Corporate Functions, tel. +358 10 426 3054, mobile +358 50 966 3054

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
http://www.orion.fi/en

http://www.twitter.com/OrionCorpIR

Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are neurological disorders, oncology and respiratory diseases for which Orion develops inhaled pulmonary medication. Orion's net sales in 2020 amounted to EUR 1,078 million and the company had about 3,300 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.